Background The efficacy of tranexamic acid (TXA) to reduce perioperative blood loss and
allogeneic blood transfusion in cardiac surgeries has been proved in previous studies, but …

Background: The optimal dose of tranexamic acid (TA) is still an issue. The authors
compared two doses of TA during cardiac surgery in a multicenter, double-blinded …

BACKGROUND Tranexamic acid (TXA) is an inexpensive therapy effective at minimizing
perioperative blood loss and transfusion. However, it remains underutilized due to safety …

Background It is unclear whether high-dose regimens of tranexamic acid in cardiac surgery
(total dose, 80 to 100 mg/kg) confer a clinical advantage over low-dose regimens (total dose …

Importance Tranexamic acid is recommended for reducing blood loss and transfusion in
cardiac surgery. However, it remains unknown whether a high dose of tranexamic acid …

Background Convulsive seizures (CS) occur in∼ 1% of the patients after cardiac surgery
with cardiopulmonary bypass. Recent investigations indicate an up to seven-fold increase in …

Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood
loss and allogeneic red blood cell transfusion in several clinical settings. With a growing …

Background Many different doses and administration schemes have been proposed for the
use of the antifibrinolytic drug tranexamic acid during cardiac surgery. This study evaluated …

Background Tranexamic acid (TXA) reduces blood transfusion in surgery but the extent of
the reduction in blood loss and how it relates to the dose of TXA is unclear. Methods A …

Objective: To review the efficacy and safety of a single dose of intravenous tranexamic acid
(TXA) given preoperatively. Summary Background Data: TXA is a synthetic antifibrinolytic …